Clinical bottom line
Current evidence on oral magnesium supplementation for atrial fibrillation (AF) prevention in primary care remains limited and inconclusive. While magnesium plays a role in cardiac electrophysiology and may influence arrhythmia risk, robust clinical trial data specifically supporting routine oral magnesium supplementation to prevent AF onset or recurrence in general practice are lacking. Clinicians should continue to prioritize established AF prevention strategies, including stroke risk assessment and anticoagulation management, while remaining alert to emerging evidence on adjunctive nutritional interventions.
What the evidence shows
Magnesium is an essential mineral involved in cardiac ion channel regulation and myocardial excitability, theoretically supporting a role in AF prevention. Some clinical studies have explored magnesium supplementation in specific contexts, such as postoperative AF prevention after cardiac surgery, with mixed results (Auer et al., 2004). However, these findings do not directly translate to primary care populations at risk for AF.
A recent cost-effectiveness analysis by Guerrero-Romero et al. (2022) evaluated oral magnesium supplementation in prediabetes management, highlighting its safety and metabolic benefits but did not address AF prevention specifically. No large-scale randomized controlled trials focusing on oral magnesium supplementation for primary prevention of AF in community or primary care settings have been published within the vetted literature.
Current AF management guidelines emphasize stroke prevention through oral anticoagulation and rhythm control strategies, with extensive evidence supporting direct oral anticoagulants (DOACs) over warfarin for non-valvular AF (Algutaini et al., 2026; Rahman et al., 2024). The role of magnesium supplementation remains adjunctive and investigational rather than standard of care.
Caveats and uncertainty
The absence of high-quality, primary care–focused trials on oral magnesium supplementation for AF prevention limits definitive conclusions. Existing studies often involve heterogeneous populations (e.g., postoperative patients) or focus on surrogate endpoints rather than clinical AF incidence or recurrence. The optimal magnesium dose, formulation, and duration for potential AF prevention are not established.
Magnesium status is rarely assessed routinely in primary care, and supplementation risks, including gastrointestinal side effects and interactions with other medications, require consideration. Additionally, the impact of magnesium supplementation on hard clinical endpoints such as stroke, hospitalization, or mortality in AF patients remains uncharacterized.
Given these uncertainties, magnesium supplementation should not replace evidence-based AF prevention and management strategies but may warrant further investigation as a complementary approach.
How this may change practice
At present, oral magnesium supplementation cannot be routinely recommended for AF prevention in primary care. Clinicians should continue to focus on established interventions, including appropriate use of oral anticoagulants guided by validated stroke risk scores and individualized patient assessment (Lau Ka Man et al., 2023; Lotufo et al., 2018).
However, in patients with documented hypomagnesemia or other indications for magnesium supplementation, clinicians may consider magnesium replacement while monitoring for efficacy and tolerability. Future research may clarify whether magnesium supplementation could serve as an adjunctive preventive measure in selected populations.
Primary care providers should stay informed about emerging evidence and integrate nutritional and metabolic considerations into holistic cardiovascular risk management.